A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment-Reference-Cited by-同舟云学术

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

Published:2019-11-19 Issue:4 Volume:182 Page:869-879
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Reich K.¹^ORCID,Augustin M.²^ORCID,Thaçi D.³,Pinter A.⁴,Leutz A.⁵,Henneges C.⁵,Schneider E.⁵,Schacht A.⁵,Dossenbach M.⁵,Mrowietz U.⁶^ORCID

Affiliation:

1. Dermatologikum Berlin and SCIderm Research Institute Hamburg Germany

2. Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

3. Institute and Comprehensive Center for Inflammation Medicine University of Lübeck University Hospital Schleswig‐Holstein Campus Lübeck Lübeck Germany

4. Department of Dermatology University Clinic of Frankfurt am Main Frankfurt am Main Germany

5. Eli Lilly and Company and/or one of its subsidiaries Indianapolis IN U.S.A

6. Psoriasis Center Department of Dermatology University Medical Center Schleswig‐Holstein Campus Kiel Kiel Germany

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18384

Reference28 articles.

1. German S3-guidelines on the treatment of psoriasis vulgaris (short version)

2. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

3. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

4. Cosentyx® (secukinumab). Summary of product characteristics. Available at:https://ec.europa.eu/health/documents/community-register/2015/20150115130444/anx_130444_en.pdf(last accessed 22 August 2019).

5. Taltz®(ixekizumab). [Summary of product characteristics]. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdf(last accessed 22 August 2019).

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis;Journal of Clinical Medicine;2024-08-29

3. Using Automated Machine Learning to Predict Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris and Psoriatic Arthritis and Uncover New Influences on Disease Progression: Retrospective Study;JMIR Formative Research;2024-06-27

4. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO);Journal of Dermatological Treatment;2024-05-26

5. The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Cureus;2024-05-24